If you have been reading about systematic review and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
| Property | Value | Notes |
|---|---|---|
| 主要靶细胞 | T细胞、树突状细胞 | 也影响NK细胞 |
| 信号通路 | TLR/MyD88/NF-κB | 部分实验模型 |
| 细胞因子偏向 | Th1型 | 增加IL-2、IFN-γ |
| 给药途径 | 皮下注射 | 临床常用 |
| 半衰期 | 约2小时 | 血浆中较短 |
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
== Education and professional development == The HGSA oversees professional training and certification in the fields of Diagnostic Genomics and Genetic Counseling. Two Boards of Censors oversee training in these two respective fields. The HGSA partners with the Royal College of Pathologists of Australasia to train senior diagnostic genomicists to become Fellows of the Faculty of Science. The Australasian Association of Clinical Geneticists (AACG), a Special Interest Group of the HGSA, has direct ties with the Royal Australasian College of Physicians (RACP), which is the body that oversees training and accreditation in clinical genetics in Australasia. The AACG advises the RACP on curricula and training requirements. In addition, members of the AACG supervise the clinical training of RACP trainees in clinical genetics. The AACG also oversees a lecture series for clinical genetics trainees. The HGSA hosts a large number of educational events throughout the year to help members undertake continuing professional development. In addition to the Society's Annual Scientific Meeting, members have access to a large number of webinars that are broadcast across Australia and New Zealand. Furthermore, each Branch holds face-to-face educational activities, such as lectures and symposia, for local members.
Since the tight control of enzyme activity is essential for homeostasis, any malfunction (mutation, overproduction, underproduction or deletion) of a single critical enzyme can lead to a genetic disease. The malfunction of just one type of enzyme out of the thousands of types present in the human body can be fatal. An example of a fatal genetic disease due to enzyme insufficiency is Tay–Sachs disease, in which patients lack the enzyme hexosaminidase. One example of enzyme deficiency is the most common type of phenylketonuria. Many different single amino acid mutations in the enzyme phenylalanine hydroxylase, which catalyzes the first step in the degradation of phenylalanine, result in build-up of phenylalanine and related products. Some mutations are in the active site, directly disrupting binding and catalysis, but many are far from the active site and reduce activity by destabilising the protein structure, or affecting correct oligomerisation. This can lead to intellectual disability if the disease is untreated. Another example is pseudocholinesterase deficiency, in which the body's ability to break down choline ester drugs is impaired. Oral administration of enzymes can be used to treat some functional enzyme deficiencies, such as pancreatic insufficiency and lactose intolerance. Another way enzyme malfunctions can cause disease comes from germline mutations in genes coding for DNA repair enzymes. Defects in these enzymes cause cancer because cells are less able to repair mutations in their genomes.
Treatment can be with oral therapy such as pentoxifylline (an anti-fibrotic phosphodiesterase inhibitor). Pentoxifylline lowers inflammation by blocking transforming growth factor beta 1 (TGF-β1), which interferes with the production of collagen type I. Pain management in the active phase of the disease can be provided by non-steroidal anti-inflammatory drugs (NSAID). One of the main symptoms of active Peyronie's disease is pain with or without erection. Pain is often distressing to patients and may compromise sexual function. Pain level should be periodically checked to measure treatment efficacy. Not recommended oral therapies include Acetyl-L-carnitine and vitamin E .
The purified compound (penicillin F) was isolated in 1940 by a research team led by Howard Florey and Ernst Boris Chain at the University of Oxford. Fleming first used the purified penicillin to treat streptococcal meningitis in 1942. The 1945 Nobel Prize in Physiology or Medicine was shared by Chain, Fleming and Florey. Several semisynthetic penicillins are effective against a broader spectrum of bacteria: these include the antistaphylococcal penicillins, aminopenicillins, and antipseudomonal penicillins.
He uses his new batteries to enlarge himself, but is deleted by the Deka Wing Cannon. Terry X is voiced by Kenji Hamada (浜田 賢二, Hamada Kenji). Kulernian Jellyfis (クラーン星人ジェリフィス, Kurān Seijin Jerifisu): A non-humanoid jellyfish-themed criminal from Planet Kulern who can take over human beings' nervous systems, which is forbidden by space law. He controls Ban, but Tetsu uses his own Super Electro Fist to briefly kill him, forcing Jellyfis off before Tetsu revives Ban with his Electro Fist technique. Jellyfis pilots the Kaijuki Million Missile in retaliation, but is deleted by Super Dekaranger Robo, which Agent Abrella takes advantage of to storm the Deka Base. Jellyfis is voiced by Kōzō Shioya (塩屋 浩三, Shioya Kōzō). Gimonian Angorl (ギモ星人アンゴール, Gimo Seijin Angōru): An anglerfish-themed criminal from Planet Gimo whom Agent Abrella broke out of prison and equipped with a Hyper Muscle Gear to assist in attacking the Deka Base via his personal Kaijuki, Abtrex, only to be deleted by the Deka Wing Cannon and Deka Bike Robo. Angorl is voiced by Keiichi Sonobe (園部 啓一, Sonobe Keiichi). Gedonian Uniga (ゲド星人ウニーガ, Gedo Seijin Unīga): A sea urchin–themed criminal from Planet Gedo and the inspiration behind the Igaroids whom Agent Abrella broke out of prison and equipped with a Hyper Muscle Gear to assist in attacking the Deka Base, only to be deleted by the Dekarangers. Uniga is voiced by Kazuya Nakai.
Sources: en.wikipedia.org
== Background == By the mid-1790s, Humboldt had devoted himself wholly to scientific investigations. Despite being offered a promotion and an increase in pay, he resigned his position as a mining official in the Prussian civil service in order to embark on a journey that would “advance him scientifically.” To the Minister of Mines in Berlin Humboldt declared: "I am considering a complete change in my mode of life, and I intend to withdraw from any official position with the state." His health, he claimed, had suffered. All he had wanted was to prepare himself for a scientific expedition by a practical employment in the mines. "As I have a deep conviction that such an expedition is highly important for increasing our knowledge of geology and physical science, I am exceedingly eager to devote my energies immediately to this end. After his mother's death in 1796, Humboldt inherited the financial means to pursue independent explorations. He decided to go to Italy, where he wanted to spend a year to a year and a half researching volcanoes. From there, he wanted to travel via Paris to England, where he would board a ship to the West Indies. However, the political instability caused by Napoleon's Italian campaign in 1797 forced Humboldt to cancel his plans. In May 1798, Humboldt traveled to Paris, where he met the botanist Aimé Bonpland. After their attempt to travel to Egypt had once again failed due to Napoleon and his campaign there, the two decided to go to Madrid in December 1798.
=== Heart disease === Macrophages are the predominant cells involved in creating the progressive plaque lesions of atherosclerosis. Focal recruitment of macrophages occurs after the onset of acute myocardial infarction. These macrophages function to remove debris, apoptotic cells and to prepare for tissue regeneration.
Multiple synthetic studies directed towards ptaquilosin 11 have been reported since 1989. In 1994, Padwa and co-workers described the synthesis of the core skeleton of ptaquilosin by a highly convergent approach. In 1995, Cossy and co-workers reported novel routes to the racemic and optically active ptaquilosin skeleton. Their properly functionalized tricyclic compound would be of great utility for the synthesis of 11.
Carlos Manuel de Céspedes was either initiated or introduced to the concept of Freemasonry during his time studying in Spain the 1840's, but as well, he studied what secret societies he could of the entire Mediterranean region from Syria to Turkey on his travels. After the death of Narciso López, in 1851, de Céspedes wrote the original version of La Bayamesa with the poet José Fornaris. In 1867, de Céspedes joined Estrella Tropical Lodge No. 19, in the town of Bayamo. Most records indicate that this was his initiation. On August 13, 1867, a meeting was held at Estrella Tropical Lodge No. 19 to discuss the revolution against the Spanish. After the meeting, Francisco Maceo Osorio turned to Perucho Figueredo, and said to him: "...now it's your turn, who are a musician, to compose our own Marseillaise." Figueredo finished the instrumental composition the next day, on August 14. On October 20, 1868, Figueredo finished the lyrics of the current version of Cuba's national anthem as the revolutionary troops entered Bayamo.
== World Accreditation Day (WAD) == NABL celebrates World Accreditation Day (WAD) every year on 9 June. World accreditation day is celebrated to provide awareness on accreditation and how accreditation benefits its stakeholders.
Sources: en.wikipedia.org
=== Peripherally restricted === Peripherally acting μ-opioid receptor antagonists are used mainly in the treatment of opioid-induced constipation. These are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, they do not affect the analgesic effects of opioids within the central nervous system.
=== Addiction === Selegiline has been evaluated for smoking cessation both as a monotherapy and in combination with nicotine replacement therapy in five clinical studies. However, it is limitedly or not effective for this use. It was also evaluated for treatment of cocaine dependence in one study, but was similarly not effective. Studies are mixed on whether selegiline, at MAO-B-selective doses, reduces the effects of cocaine in humans. Selegiline, also at an MAO-B-selective dosage, did not modify or potentiate the pharmacological effects of intravenous methamphetamine in a small clinical study.
DMSO is widely used as an alternative to water because it has a lower dielectric constant than water, and is less polar and so dissolves non-polar, hydrophobic substances more easily. It has a measurable pKa range of about 1 to 30. Acetonitrile is less basic than DMSO, and, so, in general, acids are weaker and bases are stronger in this solvent. Some pKa values at 25 °C for acetonitrile (ACN) and dimethyl sulfoxide (DMSO). are shown in the following tables. Values for water are included for comparison.
More recent data has not confirmed this association: it is thought that the disease itself is linked with a slightly higher background risk of malignancy. Ongoing data analysis on large patient populations continues in this area.
Sources: en.wikipedia.org
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。
目前认为它可能通过Toll样受体等模式识别受体传递信号，但精确的受体身份和结合机制尚未完全阐明。
不同试验在患者选择、给药方案、联合治疗和终点定义上差异很大。这些异质性使得跨研究比较困难，结论难以统一。
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。